Cart
sales@molnova.com
Hydroxychloroquine
CAS No. 118-42-3
Hydroxychloroquine( —— )
Catalog No. M23351 CAS No. 118-42-3
Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 28 | In Stock |
|
| 100MG | 36 | In Stock |
|
| 200MG | 51 | In Stock |
|
| 500MG | 85 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHydroxychloroquine
-
NoteResearch use only, not for human use.
-
Brief DescriptionHydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9.
-
DescriptionHydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetTLR
-
RecptorTLR7/9
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number118-42-3
-
Formula Weight335.87
-
Molecular FormulaC18H26ClN3O
-
Purity>98% (HPLC)
-
Solubility1M HCl : 99 mg/mL (294.75 mM; adjust pH to 2 with HCl); H2O : 1.65 mg/mL (4.91 mM; ultrasonic and warming and heat to 60°C); DMSO : < 1 mg/mL (insoluble or slightly soluble)
-
SMILESCCN(CCCC(C)Nc1c(ccc(Cl)c2)c2ncc1)CCO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017 Mar;16(3):411-419.
molnova catalog
related products
-
Isatoribine
Isatoribine (ANA245;7-Thia-8-oxoguanosine;Immunosine) is a nucleoside analogue, selective agonist of TLR7 with significant antiviral effect and mmunoenhancing activity.
-
CEP-40783
CEP-40783 is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
-
ABR-238901
ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).
